Chardan Capital将Krystal Biotech的2026财政年度收入预测提高到每股9.95美元, Chardan Capital raises Krystal Biotech's FY2026 earnings forecast to $9.95 per share, highlighting strong growth.

Chardan Capital预测Krystal生物科技在2026财政年度将获得9.95美元, Chardan Capital predicts Krystal Biotech will earn $9.95 per share in FY2026, up from the current consensus of $6.14. 生物技术公司最近报告,Q4收入为每股1.52美元。 The biotech company recently reported Q4 earnings of $1.52 per share, beating estimates. Cantor Fitzgerald和HC Wainwright也有正面的前景,Cantor设定了215美元的目标,Wainwright设定了221美元的目标。 Cantor Fitzgerald and HC Wainwright also have positive outlooks, with Cantor setting a $215 target and Wainwright a $221 target. Wainwright预测2025财政年度的收入为每股6.97美元,预测到2028年将增加。 Wainwright forecasts FY2025 earnings at $6.97 per share, with increasing projections through 2028.